Relationship between coronary tortuosity and plateletcrit coronary tortuosity and plateletcrit

Levent Cerit1, Zeynep Cerit1

  • 1Near East University Hospital, Nicosia, Cyprus.

Insights

Coronary tortuosity (CorT) is linked to higher plateletcrit (PCT), indicating increased platelet mass. This association persists even without coronary artery disease, highlighting PCT as a potential indicator for CorT.

Area of Science:

  • Cardiology
  • Hematology

Background:

  • Coronary tortuosity (CorT) is a common finding in coronary angiography.
  • CorT can be associated with myocardial ischemia, independent of coronary artery disease.
  • Platelets are key in cardiovascular disease, with larger platelets exhibiting higher activity.

Purpose of the Study:

  • To investigate the relationship between coronary tortuosity (CorT) and plateletcrit (PCT) in patients with chronic stable angina.
  • To assess if PCT is an independent predictor of CorT.

Main Methods:

  • Retrospective review of coronary angiograms from January 2013 to January 2016.
  • Inclusion of 106 patients with CorT and 108 controls with normal coronary arteries.
  • CorT defined as three fixed bends (≥ 45°) during systole and diastole.

Main Results:

  • Patients with CorT had significantly higher median PCT, mean platelet volume (MPV), platelet:large-cell ratio (P-LCR), neutrophil:lymphocyte ratio (NLR), and platelet:lymphocyte ratio (PLR) compared to controls.
  • Higher incidence of diabetes mellitus, hypertension, and female gender observed in the CorT group.
  • Multivariate analysis identified age, hypertension, diabetes mellitus, and PCT as independent predictors of CorT.

Conclusions:

  • Coronary tortuosity is associated with elevated PCT, MPV, P-LCR, NLR, and PLR, even in the absence of coronary artery disease.
  • Plateletcrit is an independent predictor of coronary tortuosity.
  • These findings suggest a role for platelet mass in the pathophysiology of CorT.
Abstract

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
817
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.1K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
347
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.6K